Johnson & Johnson raised its 2026 sales guidance to exceed $100 billion for the first time. The company's third-quarter revenue and earnings surpassed analyst expectations. Strong performance in the Innovative Medicine division, particularly oncology drugs, drove the growth.
J&J shares fell nearly 6% earlier this week following the announcement. Disappointing sales in the MedTech division missed consensus estimates and triggered the sell-off.
Institutional investor interest remains high despite the price decline. Some analysts characterize the stock's pullback as a buying opportunity.